Synthetic Society/Ownership, sharing and innovation: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
Line 58: Line 58:
*Drew Endy's talk at [http://conferences.oreillynet.com/os2005/ OSCON 2005]
*Drew Endy's talk at [http://conferences.oreillynet.com/os2005/ OSCON 2005]
**[http://web.mit.edu/endy/www/scraps/talks/05.08.05.OSCON/Endy.OSCON.2005.ppt PowerPoint]; [http://web.mit.edu/endy/www/scraps/talks/05.08.05.OSCON/Endy.OSCON.2005.pdf PDF]; [http://web.mit.edu/endy/www/scraps/talks/05.08.05.OSCON/ITC.OSCON05-DrewEndy-2005.08.05.mp3 Podcast]
**[http://web.mit.edu/endy/www/scraps/talks/05.08.05.OSCON/Endy.OSCON.2005.ppt PowerPoint]; [http://web.mit.edu/endy/www/scraps/talks/05.08.05.OSCON/Endy.OSCON.2005.pdf PDF]; [http://web.mit.edu/endy/www/scraps/talks/05.08.05.OSCON/ITC.OSCON05-DrewEndy-2005.08.05.mp3 Podcast]
*Meeting notes from Nov 2005 SynBio conference at Duke Law's Center for Study of the Public Domain [available, email endy@mit.edu]
*Meeting notes from Nov 2005 SynBio conference at [http://www.law.duke.edu/cspd/ Duke Law's Center for Study of the Public Domain] [available, email endy@mit.edu]
*[http://mitpress.mit.edu/catalog/item/default.asp?ttype=2&tid=10277 Innovation & Incentives] by Suzanne Scotchmer.
*[http://mitpress.mit.edu/catalog/item/default.asp?ttype=2&tid=10277 Innovation & Incentives] by Suzanne Scotchmer.
*[[Bbf:Notes_from_the_early_days | Notes]] & [[BioBricks_Foundation_Frequently_Asked_Questions | FAQ]] from the pre-historic days of the BioBricks Foundation.
*[[Bbf:Notes_from_the_early_days | Notes]] & [[BioBricks_Foundation_Frequently_Asked_Questions | FAQ]] from the pre-historic days of the BioBricks Foundation.
*Arti Rai and James Boyle article on legal status of Synthetic Biology [draft pending, email endy@mit.edu]
*Arti Rai and James Boyle article on legal status of Synthetic Biology [draft pending, email endy@mit.edu]
*17.310J class materials
*[http://stellar.mit.edu/S/course/17/fa05/17.310J/index.html 17.310J] [http://stellar.mit.edu/S/course/17/fa05/17.310J/materials.html class materials]
**[http://stellar.mit.edu/S/course/17/fa05/17.310J/courseMaterial/topics/topic6/readings/R-_HellerandEisenberg-Pat---terInnovation-1998/R-_HellerandEisenberg-Pat---terInnovation-1998.pdf  Can Patents Deter Innovation? The Anticommons in Biomedical Research]


==People==
==People==

Revision as of 10:28, 7 January 2006

http://www.claybennett.com/images/archivetoons/patent_pending.jpg

See also, Frank's notes. [editorial note: may want to merge them with this material.]

These notes were taken by Ken Oye and edited/posted by Reshma.

Meta-level goals

  • Create incentives to innovate
  • Limit restrictions on diffusion of fruits of innovation
  • Minimize conflicting claims that wreck both incentives and innovation
  • Maintain health of field
    • promote learning
    • avoid (premature) enclosure
    • answer the question of whether current IPR laws and TLOs will impede progress in future?

What is patentable and/or copyrightable?

  • Broad biological functions
  • Specific sequences
  • Specific uses

Answering this question requires an inventory of what has been patented, what has been challenged and what are the outcomes of adjudication. Since the record in synthetic biology is incomplete/nonexistent, we will need information on other areas that may frame decisions here like pharma, electronics, biologicals, software.

What are the positions of existing companies in synthetic biology on the IPR issues? How do they think they will play out?

Task

  • Sri will check with people at Duke Center for the Public Domain, Science Commons and the Public Patent Foundation.
  • Gautam will check with venture capitalists.

Sources of uncertainty in synthetic biology as related to IPR definitions

What are effects of alternate definitions of what is patentable and copywritable on

  1. development of field?
  2. efficiency?
  3. justice?

Technical and economic issues

  • what are the costs of innovation?
  • viability of workarounds and substitutes?
  • nearterm and medium term uses and applications of synthetic biology?

Legal and technical issues

  • are we in a potential anticommons situation? stovepiping?

Legal and risk assessment

  • liability banes that may come with property rights boons?

Task

  • Reshma and Jason and Frank will begin to identify knowns and unknowns on this.

Moving forward

  1. What strategies to change definitions of patentable?
  2. What strategies to clarify what the definitions are?
  3. What strategies GIVEN definitions of patentable?

Task

  • Sri will sort previously brainstormed strategies into relevant subcategories.

Background materials

People

Ken Oye
Reshma Shetty
Frank Field
Sriram Kosuri
Jason Kelly
Gautam Mukunda

Retrieved from "https://openwetware.org/mediawiki/index.php?title=Synthetic_Society/Ownership,_sharing_and_innovation&oldid=16371"